Investor Presentaiton
Appendix (Research and Development)
New Chemical Entity: DSP-2342
✓ Target indication: To be determined
✓ Origin: In-house (Joint research with Exscientia)
✓ Mechanism of action: Serotonin 5-HT 2A and 5-HT7 receptor antagonist
✓ Stage: Phase 1 in the U.S.
✓ Expected profile:
➤ DSP-2342 is a novel compound discovered at Sumitomo
Pharma using Exscientia's Al technologies, and is expected
to demonstrate a broad effect on psychiatric symptoms which
include psychosis, anxiety and depression, based on the
additive effect of 5-HT 2A and 5-HT7 receptor antagonist
➤ DSP-2342 has high selectivity for 5-HT 2A and 5-HT7 receptors,
which can be expected to show a high safety and tolerability
Sumitomo Pharma
5-HT2A
DSP-2342 inhibition
5-HT7
NAC
FC
PVT
VTA
Amy
Raphe
Hipp
Antidepressant
Anxiolytic
Anti-psychosis
Procognitive effect
Sleep improvement
©Sumitomo Pharma Co.,Ltd. All Rights Reserved. 27View entire presentation